Fulgent Genetics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M |
| Operating income | -$91.1M | -$73.9M | -$195.5M | $178.5M | $676.0M |
| Operating expenses | $222.0M | $181.1M | $300.0M | $188.4M | $101.1M |
| Cost of revenue | $191.8M | $176.3M | $184.8M | $252.1M | $215.5M |
| Cash from operations | -$101.6M | $21.1M | $27.0M | $253.5M | $538.6M |
| Capital expenditure | $22.6M | $40.3M | $22.2M | $18.8M | $23.8M |
| Free cash flow | -$124.2M | -$19.3M | $4.8M | $234.7M | $514.8M |
| Share repurchases | $10.9M | $225,000 | $25.1M | $74.3M | — |
| Impairments | $9.9M | $10.1M | $120.2M | — | $0 |
| Total assets | $1.2B | $1.2B | $1.2B | $1.4B | $1.3B |
| Total liabilities | $106.8M | $90.8M | $102.0M | $116.2M | $112.8M |
Shares outstanding 28.4M · Free float 32.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.